QQ客服 官方微博 反馈留言

	Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer
	Zhang, J.; Lin, Y.; Sun, X. J.; Wang, B. Y.; Wang, Z. H.; Luo, J. F.; Wang, L. P.; Zhang, S.; Cao, J.; Tao, Z. H.
刊名	ANNALS OF ONCOLOGY
	2018
卷号	29期号:8
关键词	metastatic triple-negative breast cancer progression-free survival overall survival biomarker cisplatin
ISSN号	0923-7534
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3609002
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Zhang, J.,Lin, Y.,Sun, X. J.,et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer[J]. ANNALS OF ONCOLOGY,2018,29(8).
APA	Zhang, J..,Lin, Y..,Sun, X. J..,Wang, B. Y..,Wang, Z. H..,...&Hu, X. C..(2018).Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.ANNALS OF ONCOLOGY,29(8).
MLA	Zhang, J.,et al."Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer".ANNALS OF ONCOLOGY 29.8(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。